Y-mAbs Therapeutics Inc. Stock News

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ: YMAB ) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it recently completed a Pre-Biologics License Application ("pre-BLA") meeting with the U.S. Food and Drug Administration ("FDA") regarding a potential pathway for FDA approval of omburtamab for the treatment of patients with CNS/leptomeningeal metastases from neuroblastoma. The Company expects to resubmit the BLA for omburtamab by the end of the first quarter 2022. A data readout from a single-center clinical study (Study 03-133) of omburtamab conducted at Memorial Sloan Kettering ("MSK"), where 107 evaluable patients with CNS/leptomeningeal metastases from neuroblastoma received up to two doses of radiolabeled omburtamab, showed that patients had a median survival of 50.0 months, with the final median not yet being reached.

Y-mAbs Therapeutics Inc. (NASDAQ:YMAB)s traded shares stood at 1.13 million during the last session, with the companys beta value hitting 1.28. At the close of trading, the stocks price was $7.03, to imply an increase of 1.59% or $0.11 in intraday trading. The YMAB shares 52-week high remains $50.70, putting it -621.19% down since that Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) Has Succeeded In Gaining Momentum In 2022, The Stock Is Down -56.63% YTD Read More »

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p

Y-Mabs Therapeutics Inc (YMAB) shares closed 2.2% lower than its previous 52 week low, giving the company a market cap of $548M. The stock is currently down 22.5% year-to-date, down 74.3% over the past 12 months, and down 47.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Trading volume this week was 22.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 7.8% lower than its 5-day moving average, 22.3% lower than its 20-day moving average, and 45.7% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 542.3% The company's stock price performance over the past 12 months lags the peer average by 142.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-Mabs Therapeutics Inc (YMAB) shares closed today at 0.7% above its 52 week low of $13.94, giving the company a market cap of $612M. The stock is currently down 13.4% year-to-date, down 72.7% over the past 12 months, and down 41.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 4.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 741.5% The company's stock price performance over the past 12 months lags the peer average by 141.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-Mabs Therapeutics Inc (YMAB) shares closed today at 0.7% above its 52 week low of $13.94, giving the company a market cap of $612M. The stock is currently down 13.4% year-to-date, down 72.5% over the past 12 months, and down 41.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 4.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 741.5% The company's stock price performance over the past 12 months lags the peer average by 135.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-Mabs Therapeutics Inc (YMAB) shares closed 0.2% lower than its previous 52 week low, giving the company a market cap of $660M. The stock is currently down 6.7% year-to-date, down 69.7% over the past 12 months, and down 37.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 23.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 743.0% The company's stock price performance over the past 12 months lags the peer average by 128.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-Mabs Therapeutics Inc (YMAB) shares closed today at 1.2% above its 52 week low of $14.95, giving the company a market cap of $660M. The stock is currently down 6.7% year-to-date, down 69.7% over the past 12 months, and down 37.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 21.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -726.5% The company's stock price performance over the past 12 months lags the peer average by 131.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Y-mAbs Therapeutics (NASDAQ:YMAB)s stock had its buy rating reaffirmed by investment analysts at HC Wainwright in a report released on Wednesday, TipRanks reports. They currently have a $68.00 price objective on the stock. HC Wainwrights target price suggests a potential upside of 285.27% from the companys previous close. A number of other analysts also recently [] The post Y-mAbs Therapeutics (NASDAQ:YMAB) Given Buy Rating at HC Wainwright appeared first on ETF Daily News .

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has earned a consensus recommendation of Buy from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among analysts that have []

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that […]

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time.

Brokerages forecast that Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) will post $10.98 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Y-mAbs Therapeutics earnings, with estimates ranging from $9.90 million to $12.83 million. Y-mAbs Therapeutics posted sales of $20.75 million during the same quarter last year, which []

NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the Company or Y-mAbs) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it will host a virtual research and development day on Wednesday, December 15, 2021 at 12pm Eastern Time.

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) gapped up before the market opened on Friday . The stock had previously closed at $16.04, but opened at $17.50. Y-mAbs Therapeutics shares last traded at $16.92, with a volume of 1,218 shares trading hands. A number of equities analysts have issued reports on the company. Zacks Investment Research []